Girls with precocious puberty mostly present an increased growth rate, accelerated bone maturation and may also have a compromised adult stature, in addition to psychosocial embarrassment. There is the term early puberty, which is defined by a slightly premature puberty. The question that is still outstanding is whether this condition is a normality variation or it is a pathologic process. Thinking in the second hypothesis, and with the possibility of these children do not reach their target height, some girls have been treated with GnRH analogue. The studies that evaluated the GnRH analogue in early puberty are controversial on defining if the treated girls have a final height gain compared to those who were not treated. Our hypothesis is there is no difference. Our intention is to make a systematic review of literature according to Cochrane collaboration evaluating if the treatment of girls with early puberty using GnRH analogue provides a final height improvement compared to untreated girls. The inclusion criteria for the study are: a) Participants (P): girls with early puberty who presented the larche between 7-10 years old (Tanner stage 2 or 3); b) Intervention (I): GnRH analogue treatment; c) Comparison (C): no treatment; d) Outcomes (O): primary: final height average; secondary: adverse events, psychosocial impact; e) Study Design (S): randomized clinical trials (RCTs) and, in absence of thereof, controlled clinical trials will be included. Three research strategies will be taken on the major health-related electronic databases: Embase, Pubmed and Cochrane Library. When data from more than one study are homogeneous, suitable according to the methodology employed, and with similar clinical outcomes, they will be set into a meta-analysis using the Review Manager 5.3 software.
News published in Agência FAPESP Newsletter about the scholarship: